As HIV-infected adults live longer, they are increasingly susceptible to specific cancer types. This calls for targeted cancer prevention efforts in this population.
Progress in antiretroviral research has resulted in a dramatic improvement in outcomes for HIV patients over the years. However, a new study in the Annals of Internal Medicine shows that those who have survived the retrovirus are more susceptible to malignant disease.
The authors used data from the North American AIDS Cohort Collaboration on Research and Design, during the period between 1996 and 2009. Participants included nearly 87,000 individuals with HIV and nearly 197,000 individuals without the infection. The outcome measure of the study was cumulative incidence of cancer by age 75 years based on HIV status. When analyzed based on cancer type, the authors found that HIV infection significantly increased the patient’s susceptibility to Kaposi’s sarcoma (4.5% vs 0.01%; with and without HIV), Non-Hodgkin lymphoma (4.5% vs 0.7%), lung cancer (3.4% vs 2.8%), anal cancer (1.5% vs 0.05%), liver cancer (1.1% vs 0.4%), and Hodgkin lymphoma (0.9% vs 0.09%). The authors write that reduced mortality rate for anal, colorectal, and liver cancer may be responsible for increasing cumulative incidence with those diseases.
“Pretty much across the board, cancer incidence was higher in HIV patients,” said lead study author Michael J. Silverberg, PhD, MPH, of Kaiser Permanente Division of Research, in an interview. “With these effective therapies, HIV patients are living almost normal lifespans. Before [1996], people were dying before they were old enough to get many of these diseases.”
The authors point out that their results provide impetus to cancer prevention efforts among smokers with HIV. The increased risk for liver cancer points to the need for vaccinating HIV patients against the hepatitis B virus (HBV). Those infected with HBV should be treated with antiretrovirals against HBV.
“There’s still underlying damage to the immune system and underlying inflammation that’s causing these cancers,” Silverberg said. “Even in the treated person, there is still higher risk.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More